NICE has recommended mirvetuximab soravtansine for resistant ovarian cancer, citing better survival and a less burdensome treatment experience.

We’ve recommended mirvetuximab soravtansine (also called Elahere and developed by AbbVie) for treating folate receptor-alpha-positive platinum-resistant epithelial ovarian, fallopian tube or primary ...

One in eight women will receive a diagnosis that can impact their fertility and overall health the rest of their lives.

The investigational drug extends progression-free survival in a phase 3 trial in patients with platinum-resistant or -refractory ovarian cancer.

Somewhere between 35-80% of people with PMOS experience insulin resistance, making weight management important.” ...

"If you are diagnosed with Polyendocrine Metabolic Ovarian Syndrome, it doesn't mean that you are destined to have poor ...

Discusses Preliminary Phase I Data for SIM0505 in Platinum-Resistant Ovarian Cancer and Uterine Serous Carcinoma June 2, 2026 8:00 ...

BioInvent International AB (publ) ( BOVNF) Discusses Ovarian Cancer Treatment Landscape and TNFR2-Targeted Therapies in Solid Tumors May 27, 2026 8:00 AM EDT Good morning, and welcome to the BioInvent ...

Dr. Jaclyn Smeaton, ND   A clinical review of the landmark renaming of PCOS to PMOS and why this shift reframes the condition ...

Dr. Emmalyn Pratt, ND   Subheadline Two fertility case reports exploring the potential role of ovarian platelet-rich plasma ...

An estimated 170 million people worldwide are affected by a condition called polyendocrine metabolic ovarian syndrome. The name, PMOS, was changed from PCOS after a global study, in hopes of better ...

An estimated 1 in 8 women live with polycystic ovarian syndrome, commonly referred to as PCOS. However, the name is a bit of a misnomer; it suggests that the condition affects only the ovaries. In ...